Tag
This study reveals heterogeneous clinical phenotypes in mild-to-moderate COPD, demonstrating significant variability in exacerbation risk and lung function decline, emphasizing precision medicine for early intervention.
Astegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with g
Dupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.
This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.
A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.
A recent study demonstrates that defining COPD exacerbation risk by any moderate or severe event over two years improves prediction accuracy and clinical decision-making compared to the standard one-year criteria.
The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.
This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.
In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab fo
COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su
Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.
Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.
The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients
A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.
